Lansoprazole Versus Mosapride for Functional Dyspepsia
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Functional dyspepsia is a common symptom complex with significant impact on quality of life.
There is no standard treatment for functional dyspepsia but therapeutic efficacy of proton
pump inhibitor (PPI) and prokinetic agent have been proved in subsets of patients. This study
has two aims:
- first is to compare the therapeutic efficacy of lansoprazole (a PPI) and mosapride (a
prokinetic agent) for functional dyspepsia
- second is to investigate whether different subgroups of functional dyspepsia (e.g.,
epigastric pain syndrome and postprandial distress syndrome) respond differently to PPI
and prokinetic agent.